These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30408079)

  • 21. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis.
    Nayagam S; Conteh L; Sicuri E; Shimakawa Y; Suso P; Tamba S; Njie R; Njai H; Lemoine M; Hallett TB; Thursz M
    Lancet Glob Health; 2016 Aug; 4(8):e568-78. PubMed ID: 27443782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs.
    Schackman BR; Gutkind S; Morgan JR; Leff JA; Behrends CN; Delucchi KL; McKnight C; Perlman DC; Masson CL; Linas BP
    Drug Alcohol Depend; 2018 Apr; 185():411-420. PubMed ID: 29477574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.
    Ward Z; Mafirakureva N; Stone J; Keevans M; Betts-Symonds G; Crowley D; McHugh T; Avramovic G; Lambert JS; Vickerman P
    Int J Drug Policy; 2021 Oct; 96():103394. PubMed ID: 34412938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic hepatitis B virus case-finding in UK populations born abroad in intermediate or high endemicity countries: an economic evaluation.
    Martin NK; Vickerman P; Khakoo S; Ghosh A; Ramsay M; Hickman M; Williams J; Miners A
    BMJ Open; 2019 Jun; 9(6):e030183. PubMed ID: 31256040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States.
    Chaillon A; Rand EB; Reau N; Martin NK
    Clin Infect Dis; 2019 Nov; 69(11):1888-1895. PubMed ID: 30689769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic hepatitis B and C infections in the Netherlands: estimated prevalence in risk groups and the general population.
    Koopsen J; van Steenbergen JE; Richardus JH; Prins M; Op de Coul ELM; Croes EA; Heil J; Zuure FR; Veldhuijzen IK
    Epidemiol Infect; 2019 Jan; 147():e147. PubMed ID: 30869044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
    Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
    JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of screening for chronic hepatitis C infection in the United States.
    Eckman MH; Talal AH; Gordon SC; Schiff E; Sherman KE
    Clin Infect Dis; 2013 May; 56(10):1382-93. PubMed ID: 23392392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy.
    Ruggeri M; Basile M; Coretti S; Drago C; Cicchetti A
    Appl Health Econ Health Policy; 2017 Aug; 15(4):479-490. PubMed ID: 28197805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries.
    Falla AM; Ahmad AA; Duffell E; Noori T; Veldhuijzen IK
    BMC Infect Dis; 2018 Jan; 18(1):42. PubMed ID: 29338702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation.
    Su S; Wong WC; Zou Z; Cheng DD; Ong JJ; Chan P; Ji F; Yuen MF; Zhuang G; Seto WK; Zhang L
    Lancet Glob Health; 2022 Feb; 10(2):e278-e287. PubMed ID: 35063115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Healthcare value of implementing hepatitis C screening in the adult general population in Spain.
    Buti M; Domínguez-Hernández R; Casado MÁ; Sabater E; Esteban R
    PLoS One; 2018; 13(11):e0208036. PubMed ID: 30485377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is adding HCV screening to the antenatal national screening program in Amsterdam, the Netherlands, cost-effective?
    Urbanus AT; van Keep M; Matser AA; Rozenbaum MH; Weegink CJ; van den Hoek A; Prins M; Postma MJ
    PLoS One; 2013; 8(8):e70319. PubMed ID: 23950920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of additional blood screening tests in the Netherlands.
    Borkent-Raven BA; Janssen MP; van der Poel CL; Bonsel GJ; van Hout BA
    Transfusion; 2012 Mar; 52(3):478-88. PubMed ID: 21880046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-Effectiveness of Access Expansion to Treatment of Hepatitis C Virus Infection Through Primary Care Providers.
    Rattay T; Dumont IP; Heinzow HS; Hutton DW
    Gastroenterology; 2017 Dec; 153(6):1531-1543.e2. PubMed ID: 29074450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?
    Marcellusi A; Viti R; Damele F; Cammà C; Taliani G; Mennini FS
    Clin Drug Investig; 2016 Aug; 36(8):661-72. PubMed ID: 27234943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Universal screening and treatment towards the elimination of chronic hepatitis C in China: an economic evaluation.
    Fang K; Wang HL; Lin Y; Zheng L; Li S; Wu J
    Public Health; 2024 Mar; 228():186-193. PubMed ID: 38387115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.
    Krauth C; Rossol S; Ortsäter G; Kautz A; Krüger K; Herder B; Stahmeyer JT
    BMC Infect Dis; 2019 Dec; 19(1):1019. PubMed ID: 31791253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
    Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
    Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia.
    Scott N; Iser DM; Thompson AJ; Doyle JS; Hellard ME
    J Gastroenterol Hepatol; 2016 Apr; 31(4):872-82. PubMed ID: 26514998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.